Monitor Nasdaq compliance deadline of March 30, 2026 for potential delisting impact. Watch for first use of the $50M equity line facility which could provide working capital but at significant shareholder dilution. Track progression of ART27.13 Phase 2a trial completion and data readout.
Executive Summary
Artelo Biosciences is a clinical-stage biopharmaceutical company developing therapeutics targeting lipid-signaling pathways, including the endocannabinoid system. Its lead candidates are ART27.13 for cancer-related anorexia and ART26.12 for chemotherapy-induced peripheral neuropathy. The company is raising up to $50 million through an equity line of credit with Square Gate, but faces significant risks including Nasdaq delisting, financial instability, and reliance on future financing.
Key Facts
- Company is a clinical-stage biopharmaceutical firm focused on lipid-signaling modulation pathways including the endocannabinoid system
- Lead candidate ART27.13 showed 6.38% mean weight gain vs -5.42% loss in placebo in interim Phase 2a trial for cancer anorexia
- ART26.12 completed Phase 1 trial with favorable safety profile for chemotherapy-induced peripheral neuropathy
- Facing Nasdaq delisting due to stockholders' equity below $2.5 million requirement
- Entered into $50 million equity line of credit with Square Gate but will not receive proceeds from current resale registration
- Completed 1-for-3 reverse stock split in March 2026 to improve marketability
- Has bridge notes totaling $350,300 with 12% interest issued in March 2026
Financial Impact
Up to $50 million potential gross proceeds from equity line, but immediate liquidity remains constrained
Risk Factors
- Risk of Nasdaq delisting which would severely impact stock liquidity and ability to raise capital
- Dependence on future financing to continue operations with no assurance of additional funding
- Significant shareholder dilution from equity line financing and recent reverse stock split
- Clinical trial risks including failure to demonstrate efficacy or safety issues in ongoing studies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1 Filing (Primary) | 0001640334-26-000543 |
| Document: artl_ex107.htm | 0001640334-26-000543 |
| Document: artl_ex51.htm | 0001640334-26-000543 |
| Document: artl_ex231.htm | 0001640334-26-000543 |
| Document: 0001640334-26-000543-index-headers.html | 0001640334-26-000543 |
| Document: 0001640334-26-000543-index.html | 0001640334-26-000543 |
| Document: 0001640334-26-000543.txt | 0001640334-26-000543 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | 8-K | $3.11 | awaiting T+60 | — | $2.20 (+29.26%) |
Sep 16, 2026 5w ago | Press Release | $3.75 | awaiting T+60 | — | $2.20 (−41.33%) |
Aug 13, 2026 10w ago | Press Release | $6.83 | awaiting T+60 | — | $2.20 (−67.79%) |
Jul 16, 2026 14w ago | DEFA14A | $1.14 $0.3622 | ▼ −68.23% | ▼ −71.94% | $2.20 (+92.98%) |
Jul 16, 2026 14w ago | Press Release | $1.14 $0.3622 | ▼ −68.23% | ▼ −71.94% | $2.20 (+92.98%) |
Jul 13, 2026 15w ago | Press Release | $1.05 $0.3844 | ▼ −63.39% | ▼ −67.38% | $2.20 (+109.52%) |
Jul 2, 2026 16w ago | DEFA14A | $1.11 $0.4522 | ▲ +59.26% | ▲ +60.98% | $2.20 (−98.20%) |
May 27, 2026 21w ago | 8-K | $1.46 $0.6920 | ▲ +52.60% | ▲ +54.34% | $2.20 (−50.68%) |
May 18, 2026 23w ago | 424B5 | $1.36 $0.7587 | ▼ −44.21% | ▼ −50.50% | $2.20 (+61.76%) |
May 15, 2026 23w ago | 8-K | $1.46 $0.7330 | ▼ −49.79% | ▼ −54.65% | $2.20 (+50.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers